These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 2696031)

  • 1. Significant survival benefit of node-negative breast cancer patients treated with adjuvant chemotherapy: seven-year results.
    Jakesz R; Reiner G; Schemper M; Reiner A; Blijham G; Rainer H; Dittrich D; Spona J; Schutte B; Reynders M
    Recent Results Cancer Res; 1989; 115():180-5. PubMed ID: 2696031
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant chemotherapy for node-negative breast cancer patients.
    Bonadonna G; Zambetti M; Valagussa P
    Recent Results Cancer Res; 1989; 115():175-9. PubMed ID: 2516350
    [No Abstract]   [Full Text] [Related]  

  • 3. Chemo- or endocrine adjuvant therapy alone or combined in postmenopausal patients (GABG Trial 1).
    Jonat W; Kaufmann M; Abel U
    Recent Results Cancer Res; 1989; 115():163-9. PubMed ID: 2696028
    [No Abstract]   [Full Text] [Related]  

  • 4. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
    Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study.
    Mansour EG; Gray R; Shatila AH; Osborne CK; Tormey DC; Gilchrist KW; Cooper MR; Falkson G
    N Engl J Med; 1989 Feb; 320(8):485-90. PubMed ID: 2915651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormone receptors. An update and application.
    Hubay CA; Arafah B; Gordon NH; Guyton SP; Crowe JP
    Surg Clin North Am; 1984 Dec; 64(6):1155-72. PubMed ID: 6393400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant chemo- and endocrine therapy alone or in combination in premenopausal patients (GABG Trial 1).
    Kaufmann M; Jonat W; Abel U
    Recent Results Cancer Res; 1989; 115():118-25. PubMed ID: 2696024
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil.
    Miles DW; Harris WH; Gillett CE; Smith P; Barnes DM
    Int J Cancer; 1999 Aug; 84(4):354-9. PubMed ID: 10404085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant immunotherapy in node-negative patients: results of a Scandinavian study.
    Nissen-Meyer R; Host H; Kjellgren K
    Recent Results Cancer Res; 1989; 115():186-90. PubMed ID: 2696032
    [No Abstract]   [Full Text] [Related]  

  • 10. Ludwig Breast Cancer trial LBCS III: chemo- and endocrine adjuvant treatment in postmenopausal patients.
    Gelber RD
    Recent Results Cancer Res; 1984; 96():102-9. PubMed ID: 6396763
    [No Abstract]   [Full Text] [Related]  

  • 11. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer.
    Ludwig Breast Cancer Study Group
    N Engl J Med; 1989 Feb; 320(8):491-6. PubMed ID: 2644533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scottish adjuvant breast cancer trials: results in pre-menopausal patients.
    Stewart HJ
    Recent Results Cancer Res; 1989; 115():126-31. PubMed ID: 2696025
    [No Abstract]   [Full Text] [Related]  

  • 13. How to improve adjuvant treatment results in postmenopausal patients.
    Mouridsen HT
    Recent Results Cancer Res; 1989; 115():144-52. PubMed ID: 2533698
    [No Abstract]   [Full Text] [Related]  

  • 14. Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node-positive adjuvant CMFVP breast cancer data base: a pilot study.
    Albain KS; Green S; LeBlanc M; Rivkin S; O'Sullivan J; Osborne CK
    Breast Cancer Res Treat; 1992; 22(3):273-84. PubMed ID: 1391993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-course FAC-M versus 1 year of CMFVP in node-positive, hormone receptor-negative breast cancer: an intergroup study.
    Budd GT; Green S; O'Bryan RM; Martino S; Abeloff MD; Rinehart JJ; Hahn R; Harris J; Tormey D; O'Sullivan J
    J Clin Oncol; 1995 Apr; 13(4):831-9. PubMed ID: 7707108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled trial of adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil for breast cancer.
    Howell A; Bush H; George WD; Howat JM; Crowther D; Sellwood RA; Rubens RD; Hayward JL; Bulbrook RD; Fentiman IS
    Lancet; 1984 Aug; 2(8398):307-11. PubMed ID: 6146861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant treatment in node-negative, postmenopausal breast cancer.
    Hutchins LF; Arick CL
    Cancer Invest; 2001; 19(7):706-22. PubMed ID: 11577812
    [No Abstract]   [Full Text] [Related]  

  • 18. Adjuvant systemic treatment of resectable breast cancer: eleven years results of a monoinstitutional chemo-hormone-immunotherapy trial.
    Rosso R; Boccardo F; Brema F; Sertoli MR; Amoroso D; Bertelli G; Pronzato P
    Anticancer Res; 1989; 9(4):1153-6. PubMed ID: 2817796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant systemic therapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group's trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients.
    Mouridsen HT; Rose C; Brincker H; Thorpe SM; Rank F; Fischerman K; Andersen KW
    Recent Results Cancer Res; 1984; 96():117-28. PubMed ID: 6396765
    [No Abstract]   [Full Text] [Related]  

  • 20. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
    Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
    J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.